Evaxion AS
EVAX
Company Profile
Business description
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients’ lives by providing innovative and targeted treatment options.
Contact
Dr. Neergaards Vej 5f
Hoersholm2970
DNKT: +45 31319753
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
46
Stocks News & Analysis
stocks
Are small caps finally back?
Does renewed investor interest point to a structural shift in the underperforming factor?
stocks
Chart of the Week: Modest earnings growth at odds with overvalued bank shares
The latest update from our Industry Pulse report.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,295.30 | 17.10 | 0.18% |
| CAC 40 | 8,206.87 | 51.99 | -0.63% |
| DAX 40 | 24,151.13 | 178.90 | -0.74% |
| Dow JONES (US) | 46,590.41 | 334.33 | -0.71% |
| FTSE 100 | 9,515.00 | 88.01 | 0.93% |
| HKSE | 25,781.77 | 245.78 | -0.94% |
| NASDAQ | 22,740.40 | 213.27 | -0.93% |
| Nikkei 225 | 48,576.09 | 731.70 | -1.48% |
| NZX 50 Index | 13,346.03 | 39.59 | 0.30% |
| S&P 500 | 6,699.40 | 35.95 | -0.53% |
| S&P/ASX 200 | 9,001.30 | 15.10 | 0.17% |
| SSE Composite Index | 3,913.76 | 2.57 | -0.07% |